BCRX

Rating buyAI Memo

BioCryst

As of 2026-09-02/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

6‑12m

Key catalyst

ORLADEYO pediatric oral-pellet rollout • 2026-08-03

Base target: $11 / p=55% prob

Biggest risk

Core ORLADEYO growth was modest on a reported basis, pediatric paid-therapy conversion is still unproven, BCX17725 remains early-stage, and navenibart carries clinical and regulatory risk. Q2 revenue also benefited from licensing-related recognition that may not recur at the same level.

Invalidation

Break below $8 or thesis failure.

What would change my mind?

ORLADEYO remains the commercial anchor, Q2 revenue and positive cash flow were strong, total-revenue guidance increased, pediatric pellets broaden the addressable treated population, and completed navenibart enrollment provides a defined longer-term franchise catalyst. [#SEC-8K-2026-08-05]

Research note

Recommendation

buy

Confidence

medium

As of

2026-09-02

Base target

$11

p=55%

Bull target

$12

p=25%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 results and raised total-revenue outlook
BCX17725 Netherton syndrome data
Navenibart ALPHA-ORBIT readout

BearKey bullets

BCX17725 remains an early clinical program and may not generate positive year-end data.
Licensing-related revenue recognition and the upfront payment may make Q2 profitability less representative of recurring operations.
Navenibart may produce unfavorable efficacy, safety, regulatory, or competitive outcomes.

WatchKey bullets

ORLADEYO pediatric oral-pellet rollout

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $11 (p=55%)

Target spread vs base: +10% / -26%

Scenario probabilities

Bull Target: $12 (p=25%)Base Target: $11 (p=55%)Bear Target: $8 (p=20%)

Commentary

News tone is constructive after the Q2 update, raised total-revenue guidance, pediatric pellet launch, and completed navenibart enrollment. The stored earnings context also cites positive cash generation, improving ORLADEYO paid rate, and disciplined spending. However, social coverage is unavailable, and post-release price reaction, analyst revisions, options skew, short interest, and employee sentiment were not supplied; missing data is not positive evidence. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-12]

As of 2026-09-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 results and raised total-revenue outlook
BCX17725 Netherton syndrome data
Navenibart ALPHA-ORBIT readout

Scenarios

Bull Target (Scenario probability)

$12 / p=25% prob

Base Target (Scenario probability)

$11 / p=55% prob

Bear Target (Scenario probability)

$8 / p=20% prob

Analysis 2026-09-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.65

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-03
ORLADEYO pediatric oral-pellet rollout
Initial pediatric oral-pellet shipments began the week of August 3. The company reported 47 prescriptions year-to-date, with more than half having completed prior authorization and a high approval rate; paid conversion and real-world outcomes remain unproven. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-12]
Prob 80.00% • Move 8.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

Q2 results and raised total-revenue outlook
2026-08-05
BioCryst reported Q2 total revenue of $218.3 million and raised full-year 2026 total-revenue guidance to $690-$715 million while maintaining ORLADEYO guidance at $625-$645 million. The results were reported through the SEC filing and attached release. [#SEC-8K-2026-08-05]
Prob 85% • Move 6% • Priced-in 75%

Long-term Catalysts

Months to a year

BCX17725 Netherton syndrome data
2026-12-31
The Phase 1 BCX17725 trial is dosing its final reported part, with data expected by the end of 2026. This remains an early clinical program with meaningful development risk. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-12]
Prob 55% • Move 12% • Priced-in 35%
Navenibart ALPHA-ORBIT readout
2027-09-02
Enrollment in the pivotal hereditary-angioedema ALPHA-ORBIT study was completed, with top-line results for quarterly and semiannual dosing expected in Q3 2027. Positive data could extend the HAE franchise, but clinical and regulatory risk is high. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-12]
Prob 50% • Move 18% • Priced-in 25%

Risks

BCX17725 remains an early clinical program and may not generate positive year-end data.
Licensing-related revenue recognition and the upfront payment may make Q2 profitability less representative of recurring operations.
Navenibart may produce unfavorable efficacy, safety, regulatory, or competitive outcomes.
Pediatric oral-pellet prescriptions may not convert into durable paid therapy or sustained demand.
Post-earnings analyst revisions, options data, short interest, and market-reaction attribution are unavailable.

Peers

Symbol	Summary
PHVS	Closest listed HAE-focused comparator and relevant operating peer for ORLADEYO and navenibart; valuation comparability remains limited by different development and commercial stages.
COAG	Similarly sized rare-disease biotech candidate, but the packet provides no operating metrics, making comparability loose.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-02

Loading AI feed…

Symbol

Summary

PHVS

Closest listed HAE-focused comparator and relevant operating peer for ORLADEYO and navenibart; valuation comparability remains limited by different development and commercial stages.

COAG

Similarly sized rare-disease biotech candidate, but the packet provides no operating metrics, making comparability loose.